<DOC>
	<DOCNO>NCT02991066</DOCNO>
	<brief_summary>Although clinical application differentiation therapy make great success treatment acute promyelocytic leukemia ( APL ) , early fatal bleeding remain unsolved problem account main reason induction failure APL patient . The clinical manifestation serious bleed thrombosis illustrate complexity pathogenesis coagulopathy APL . Despite extensive research , pathogenesis coagulopathy APL still unclear . Microparticles , 0.11μm diameter , small membrane vesicle release circulation blood cell vascular endothelial cell activation apoptosis . Microparticles ( MPs ) derive different cell type exert procoagulant activity mediate phosphatidylserine ( PS ) carry basic substance derive origin cell . Also , biological activity microparticles often significantly high cell come . According problem background knowledge , project aim observe role microparticles derive APL cell procoagulant profibrinolytic activate factor reside microparticles pathogenesis coagulopathy APL , effect different induction therapy , chemotherapeutic drug differentiation agent microparticles procoagulant profibrinolytic activating factor . To carry study , microparticles obtain patient undergo different induction therapy different time point primary bone marrow APL cell treat different drug vitro different time point , expression activity five procoagulant profibrinolytic activating factor , highly express APL cell , PS exposure functional state microparticles , dynamically monitor . Further study pathogenesis coagulopathy APL provide clue help deep understanding clinical manifestation , guide clinical treatment well judge prognosis , establish theoretical basis explore new treatment .</brief_summary>
	<brief_title>Role Microparticles Coagulopathy Acute Promyelocytic Leukemia</brief_title>
	<detailed_description>The investigator plan measure routine laboratory parameter coagulation fibrinolysis , procoagulant profibrinolytic activity microparticles ( MPs ) , explore role procoagulant profibrinolytic activate factor MPs pathogenesis coagulopathy patient APL . . Dynamic turbidimetry plasma clot formation . The effect MPs kinetics fibrin formation optical property clot study use dynamic turbidimetry re-calcified plasma sample ( platelet-free plasma microparticle-depleted plasma ) without add clot activator . Clotting plasma sample induce Ca2+ follow monitor optical density λ = 405 nm 37 °C . ii . Thrombin generation assay . The amount thrombin form plasma upon re-calcification measure directly use modify thrombin generation test . Because fibrin interferes colorimetric measurement , plasma sample first defibrinate add reptilase follow incubation 37 °C . The clot remove . Then chromogenic substrate thrombin add plasma sample . Thrombin generation start add CaCl2 simultaneous record absorbance λ = 405 nm . iii . Thrombin generate capacity MPs . MPs reconstitute defibrinate ( reptilase treat ) , normal pool microparticle-depleted plasma . Then chromogenic substrate thrombin add sample . Thrombin generation start add CaCl2 simultaneous record absorbance λ = 405 nm . iv . Thrombin generation inhibitory experiment . The following inhibitor pre-incubated microparticles : Annexin V , anti-human tissue factor ( TF ) irrelevant control immunoglobulin G ( IgG ) . Then repeat experiment iii . v. Fibrinolytic activity . Incubate fixed concentration plasminogen plasma sample presence chromogenic substrate selective plasmin . Plasmin form plasminogen bound surface microparticles cleave chromogenic substrate release p-nitroaniline detect measure A405nm function time . vi . Determination fibrinolytic activity microparticles . The capacity microparticles activate plasminogen determine incubate fix concentration plasminogen ( 1mM ) microparticles without t-PA and/or u-PA presence chromogenic substrate selective plasmin . Plasmin form plasminogen bound surface microparticles cleave chromogenic substrate release p-nitroaniline detect measure A405nm . vii . Fibrinolytic activity inhibitory experiment . The following inhibitor pre-incubated microparticles : anti-human tissue type plasminogen activator ( tPA ) , anti-human urokinase type plasminogen activator ( uPA ) , respective irrelevant control IgGs ; ε-aminocaproic acid plasminogen activator inhibitor-1 ( PAI-1 ) .Then repeat experiment vi .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Promyelocytic , Acute</mesh_term>
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<criteria>Patients de novo APL accompany hemorrhage . The diagnosis confirm presence ( 15 ; 17 ) and/or PML ( promyelocytic leukemia ) /RARa ( retinoic acid receptor alpha ) fusion gene . Patients receive singleagent arsenic trioxide ( ATO ) induction therapy . Patients relapse acute promyelocytic leukemia . Patients without evidence bleeding . Patients young 18 year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Acute promyelocytic leukemia</keyword>
	<keyword>Coagulopathy</keyword>
	<keyword>Microparticles</keyword>
	<keyword>Mechanism</keyword>
</DOC>